← Back to Search

Monoclonal Antibodies

Atezolizumab + Bevacizumab for Kidney Cancer

Phase 2

Waitlist Available

Led By Toni Choueiri, MD

Research Sponsored by Dana-Farber Cancer Institute

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Adequate hematologic and end-organ function as defined by specific laboratory results

Age ≥ 18 years

Must not have

History of autoimmune diseases or specific pulmonary conditions

Prior treatment with specific therapeutic antibodies or pathway targeting agents

Timeline

Screening 3 weeks

Treatment Varies

Follow Up 1 year

Awards & highlights

Summary

This trial is testing a new combination treatment for advanced kidney cancer that has not responded to other treatments.

Who is the study for?

Adults with advanced non-clear cell kidney cancer, including various subtypes like Papillary RCC and Chromophobe RCC. Participants must have measurable disease, be in relatively good health (ECOG ≤ 2), able to follow study procedures, and use effective contraception. Excluded are those with recent significant cardiovascular events, organ transplants, active infections like HIV or hepatitis B/C, certain allergies or hypersensitivities to trial drugs' components, other cancers within the last two years (with exceptions), brain metastases unless stable for at least four weeks.

What is being tested?

The trial is testing a combination of Atezolizumab and Bevacizumab as potential treatments for advanced non-clear cell kidney cancer. It aims to see how well these drugs work together in treating this specific type of cancer.

What are the potential side effects?

Possible side effects include allergic reactions to the drug components; increased risk of infection; high blood pressure; proteinuria which is excess protein in urine indicating kidney damage; bleeding issues; gastrointestinal complications such as fistulas or perforations; and potentially severe skin reactions.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below

Select...

My blood and organ tests meet the required health standards.

Select...

I am 18 years old or older.

Select...

I can take care of myself but might not be able to do heavy physical work.

Exclusion Criteria

You may be eligible for the trial if you check “No” for criteria below:

Select...

I have a history of autoimmune diseases or specific lung conditions.

Select...

I have been treated with drugs targeting specific cancer pathways.

Select...

I have been treated with bevacizumab before.

Select...

I have serious wounds, ulcers, or protein in my urine.

Select...

I have had a major surgery or organ transplant recently.

Select...

I have had issues like a hole in my stomach or throat, or a blockage in my intestines.

Select...

I do not have serious heart disease or high blood pressure that is not well controlled.

Select...

I have a history of stroke, vascular disease, or bleeding problems.

Select...

I have had cancer other than kidney cancer within a specific timeframe.

Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ 1 year

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~1 year

This trial's timeline: 3 weeks for screening, Varies for treatment, and 1 year for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.

Primary study objectives

Best Overall Response Rate

Secondary study objectives

1-Year Overall Survival

1-Year Overall Survival by Histological Subgroup

1-Year Overall Survival by International Metastatic Renal Cell Carcinoma Risk Group

+16 more

Trial Design

1Treatment groups

Experimental Treatment

Group I: Bevacizumab And Atezolizumab CombinationExperimental Treatment2 Interventions

1200 mg of Atezolizumab intravenously x 3 weeks 15 mg/kg of Bevacizumab intravenously x 3 weeks. One cycle will be 3 weeks in duration.

Treatment

First Studied

Drug Approval Stage

How many patients have taken this drug

Bevacizumab

2013

Completed Phase 4

~5540

Atezolizumab

2017

Completed Phase 3

~5850

0 / 12Eligibility criteria met

Find a Location

Who is running the clinical trial?

Dana-Farber Cancer InstituteLead Sponsor

1,100 Previous Clinical Trials

353,032 Total Patients Enrolled

Genentech, Inc.Industry Sponsor

1,550 Previous Clinical Trials

568,299 Total Patients Enrolled

Toni Choueiri, MDPrincipal InvestigatorDana-Farber Cancer Institute

4 Previous Clinical Trials

207 Total Patients Enrolled

Media Library

Atezolizumab (Monoclonal Antibodies) Clinical Trial Eligibility Overview. Trial Name: NCT02724878 — Phase 2

Renal Cell Carcinoma Research Study Groups: Bevacizumab And Atezolizumab Combination

Renal Cell Carcinoma Clinical Trial 2023: Atezolizumab Highlights & Side Effects. Trial Name: NCT02724878 — Phase 2

Atezolizumab (Monoclonal Antibodies) 2023 Treatment Timeline for Medical Study. Trial Name: NCT02724878 — Phase 2

~7 spots leftby Sep 2025

Unbiased ResultsWe believe in providing patients with all the options.

Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.

Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.